Hopes were high for a rebound in capital-markets activity this year A few notable Health Care deals along with M&A in the ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

We recently compiled a list of the Jim Cramer Discusses These 10 Stocks & Comments On OpenAI’s Valuation. In this article, we ...

Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government health plan coverage.

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Dublin-based accessibility start-up Mobility Mojo will receive €4.25m in investment from UK-based equity investor Gresham ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Venture capital (VC) thrives on risk ... and pivots quickly when strategies fall short. Now, AH and Eli Lilly are rewriting the playbook with a pioneering Biotech Ecosystem Fund.